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BACKGROUND
Conflicting evidence exists on the efficacy and safety of bivalirudin administered 
as part of percutaneous coronary intervention (PCI) in patients with an acute 
coronary syndrome.
METHODS
We randomly assigned 7213 patients with an acute coronary syndrome for whom 
PCI was anticipated to receive either bivalirudin or unfractionated heparin. Patients 
in the bivalirudin group were subsequently randomly assigned to receive or not to 
receive a post-PCI bivalirudin infusion. Primary outcomes for the comparison be-
tween bivalirudin and heparin were the occurrence of major adverse cardiovascular 
events (a composite of death, myocardial infarction, or stroke) and net adverse 
clinical events (a composite of major bleeding or a major adverse cardiovascular 
event). The primary outcome for the comparison of a post-PCI bivalirudin infusion 
with no post-PCI infusion was a composite of urgent target-vessel revascularization, 
definite stent thrombosis, or net adverse clinical events.
RESULTS
The rate of major adverse cardiovascular events was not significantly lower with 
bivalirudin than with heparin (10.3% and 10.9%, respectively; relative risk, 0.94; 
95% confidence interval [CI], 0.81 to 1.09; P = 0.44), nor was the rate of net adverse 
clinical events (11.2% and 12.4%, respectively; relative risk, 0.89; 95% CI, 0.78 to 
1.03; P = 0.12). Post-PCI bivalirudin infusion, as compared with no infusion, did not 
significantly decrease the rate of urgent target-vessel revascularization, definite 
stent thrombosis, or net adverse clinical events (11.0% and 11.9%, respectively; 
relative risk, 0.91; 95% CI, 0.74 to 1.11; P = 0.34).
CONCLUSIONS
In patients with an acute coronary syndrome, the rates of major adverse cardiovas-
cular events and net adverse clinical events were not significantly lower with bi-
valirudin than with unfractionated heparin. The rate of the composite of urgent 
target-vessel revascularization, definite stent thrombosis, or net adverse clinical 
events was not significantly lower with a post-PCI bivalirudin infusion than with 
no post-PCI infusion. (Funded by the Medicines Company and Terumo Medical; 
MATRIX ClinicalTrials.gov number, NCT01433627.)
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The most effective antithrombotic regimen for preventing ischemic complica-tions while limiting bleeding risk in pa-
tients with an acute coronary syndrome who are 
undergoing invasive treatment remains unknown.1-3 
Two of the most commonly used antithrombotic 
regimens worldwide4,5 are unfractionated heparin, 
an indirect thrombin inhibitor, with or without 
the concomitant use of a glycoprotein IIb/IIIa 
inhibitor, and bivalirudin, a direct thrombin in-
hibitor, with a glycoprotein IIb/IIIa inhibitor 
added only for periprocedural ischemic complica-
tions. Previous studies that have compared these 
two options among patients who were undergo-
ing invasive treatment for an acute coronary 
syndrome have provided conflicting results with 
respect to ischemic, bleeding, or combined out-
comes.3,6-10 We therefore conducted a large multi-
center, randomized trial involving patients with 
an acute coronary syndrome who were undergo-
ing coronary angiography and anticipated percu-
taneous coronary intervention (PCI) with access 
through the radial or femoral route to assess 
whether bivalirudin is superior to unfractionated 
heparin and discretionary use of glycoprotein 
IIb/IIIa inhibitors.
Me thods
Study Design
Minimizing Adverse Hemorrhagic Events by Trans-
radial Access Site and Systemic Implementation 
of Angiox (MATRIX) was a program of three 
randomized, multicenter, open-label superiority 
trials involving patients with an acute coronary 
syndrome.11,12 The results of the first trial, in 
which we compared transradial access with 
transfemoral access in 8404 patients, were re-
ported previously.11,12 Here, we report on the two 
other, nested trials, which were conducted as 
additional randomized comparisons in subgroups 
of patients. MATRIX Antithrombin was a ran-
domized comparison of bivalirudin and unfrac-
tionated heparin involving 7213 patients with ST-
segment elevation myocardial infarction (STEMI) 
or a non–ST-segment elevation acute coronary 
syndrome for whom PCI was planned. MATRIX 
Treatment Duration was a randomized compari-
son of prolonged bivalirudin administration with 
a post-PCI infusion with short-term bivalirudin 
administration without a post-PCI infusion, in the 
3610 patients who were assigned to receive bi-
valirudin.11,12
Study Support and Oversight
The MATRIX program was designed by the first 
author and approved by the institutional review 
board at each participating center. The study was 
sponsored by the Italian Society of Invasive Car-
diology (GISE), a nonprofit organization, and 
received grant support from the Medicines Com-
pany and Terumo Medical. (Details are provided 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org.) The 
Medicines Company provided bivalirudin for the 
trial; otherwise, the sponsor and funders had no 
role in the design of the study, the collection, 
monitoring, analysis, and interpretation of the 
data, or the writing of the report. Both the spon-
sor and the Medicines Company (one of the 
funders) reviewed the manuscript but did not 
provide any comments with respect to the con-
tent. The first draft of the manuscript was writ-
ten by the first author with the assistance of the 
other authors and with limited editing for style 
by MedLink Healthcare Communications (fund-
ed by GISE). All the authors vouch for the accu-
racy and completeness of the data and all analy-
ses and for the fidelity of this report to the trial 
protocol, which is available at NEJM.org.
Patients
Patients with non–ST-segment elevation acute 
coronary syndromes were eligible if they had a 
history consistent with new or worsening car-
diac ischemia, occurring while they were at rest 
or with minimal activity within 7 days before 
randomization, and met at least two high-risk 
criteria among the following: an age of 60 years 
or older, an elevation in cardiac biomarkers, or 
electrocardiographic changes compatible with 
ischemia; and if they were considered to be can-
didates for PCI after completion of coronary 
angiography. Patients with STEMI were eligible 
if they presented within 12 hours after the on-
set of symptoms or between 12 and 24 hours 
after symptom onset if there was evidence of 
continuing ischemia or previous fibrinolytic 
treatment. Detailed inclusion and exclusion 
criteria are provided in the Supplementary Ap-
pendix. All patients provided written informed 
consent.11
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Study Protocol and Randomization
Patients were randomly assigned, in a 1:1 ratio, 
to receive bivalirudin or unfractionated heparin. 
Patients who were assigned to the bivalirudin 
group were subsequently randomly assigned, in 
a 1:1 ratio, to receive a post-PCI bivalirudin infu-
sion or no post-PCI infusion. Central randomiza-
tion was concealed with the use of a Web-based 
system; randomization sequences were computer 
generated, blocked, and stratified according to 
the intended new or ongoing use of a P2Y12 in-
hibitor (clopidogrel vs. ticagrelor or prasugrel) 
and type of acute coronary syndrome (STEMI vs. 
troponin-positive vs. troponin-negative non–ST-
elevation acute coronary syndrome). Patients with 
STEMI underwent randomization before coronary 
angiography; patients with non–ST-elevation 
acute coronary syndrome underwent randomiza-
tion immediately after completion of angiogra-
phy but before the start of PCI.
All interventions were administered in an open-
label fashion. Bivalirudin was given according to 
the product labeling, with a bolus of 0.75 mg per 
kilogram of body weight, followed immediately 
by an infusion of 1.75 mg per kilogram per hour 
until completion of the PCI. Bivalirudin was 
then stopped at the end of PCI or prolonged in 
accordance with the subsequent random assign-
ment. Among patients who were assigned to 
receive prolonged treatment, bivalirudin could 
be administered either at the full dose for up to 
4 hours or at a reduced dose of 0.25 mg per kilo-
gram per hour for at least 6 hours, with the 
choice between those two regimens made at the 
discretion of the treating physicians.11 Heparin 
was administered at a dose of 70 to 100 units per 
kilogram in patients not receiving glycoprotein 
IIb/IIIa inhibitors and at a dose of 50 to 70 units 
per kilogram in patients receiving glycoprotein 
IIb/IIIa inhibitors. Subsequent adjustment of the 
heparin dose on the basis of the activated clot-
ting time was left to the discretion of the treat-
ing physicians.
A glycoprotein IIb/IIIa inhibitor could be ad-
ministered before PCI in all patients in the 
heparin group on the basis of the treating physi-
cian’s judgment, but the drug was to be admin-
istered in the bivalirudin group only in patients 
who had periprocedural ischemic complications 
(i.e., no reflow or giant thrombus) after PCI. The 
use of other medications was allowed according 
to professional guidelines.13,14 Information on 
specific protocol guidance with regard to staged 
procedures and post-procedure use of unfrac-
tionated heparin is provided in the Supplemen-
tary Appendix.
Follow-up and Outcomes
Clinical follow-up was performed at 30 days. 
Coprimary outcomes for MATRIX Antithrombin 
were major adverse cardiovascular events, which 
were defined as a composite of death from any 
cause, myocardial infarction, or stroke, up to 
30 days, and net adverse clinical events, which 
were defined as a composite of major bleeding 
that was not related to coronary-artery bypass 
grafting (CABG) (Bleeding Academic Research 
Consortium [BARC] type 3 or 515) or major ad-
verse cardiovascular events, up to 30 days. The 
primary outcome for MATRIX Treatment Dura-
tion was a composite of urgent target-vessel re-
vascularization, definite stent thrombosis, or net 
adverse clinical events up to 30 days.11
Secondary outcomes included each component 
of the composite outcomes, death from cardio-
vascular causes, and stent thrombosis. Bleeding 
was also assessed and adjudicated on the basis 
of the Thrombolysis in Myocardial Infarction 
(TIMI)16 and Global Utilization of Streptokinase 
and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO17) scales. All outcomes 
were prespecified.11
An independent clinical-events committee 
whose members were unaware of study-group 
assignments adjudicated all suspected events. 
Detailed definitions of outcomes and procedures 
of the clinical-events committee are provided in 
the Supplementary Appendix.
Statistical Analysis
The MATRIX program was designed to include 
three independent, albeit nested, trials, with 
separate sample-size considerations prespecified 
for each trial. MATRIX Antithrombin was pow-
ered for an analysis of superiority regarding its 
two coprimary composite outcomes at 30 days. 
For major adverse cardiovascular events, we ex-
pected rates of 6.0% in the heparin group and 
4.2% in the bivalirudin group; for net adverse 
clinical events, we expected rates of 9.0% in the 
heparin group and 6.3% in the bivalirudin group. 
These two between-group differences correspond 
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to a rate ratio of 0.70. We determined that the 
enrollment of 3400 patients in each study group 
would provide a power of 85% and 95%, respec-
tively, for these differences to be detected at a 
two-sided alpha level of 0.025. For MATRIX 
Treatment Duration, we assumed that the inci-
dence of the composite of death, myocardial 
infarction, stroke, urgent target-vessel revascu-
larization, definite stent thrombosis, or BARC 
type 3 or 5 bleeding at 30 days would be 10.0% 
with short-term bivalirudin and 7.0% with pro-
longed bivalirudin, corresponding again to a 
rate ratio of 0.70. We determined that the enroll-
ment of 1700 patients in each study group would 
provide a power of 86% to detect this difference 
at a two-sided alpha level of 0.05. Details regard-
ing the statistical analysis have been reported 
previously11,12 and are provided in the Supple-
mentary Appendix. Percentages that are report-
ed for outcomes are Kaplan–Meier estimates of 
cumulative incidence.
R esult s
Patients and Procedures
From October 11, 2011, to November 7, 2014, at 
78 centers in Italy, the Netherlands, Spain, and 
Sweden, 3610 patients were assigned to receive 
bivalirudin, either with a post-PCI infusion 
(1799 patients) or without a post-PCI infusion 
(1811 patients), and 3603 were assigned to re-
ceive heparin (Fig. S1A and S1B in the Supple-
mentary Appendix). Of these patients, 3442 (95.3%) 
in the bivalirudin group and 3473 (96.4%) in the 
heparin group received the assigned intervention.
The baseline features were similar among the 
groups (Tables 1 and 2). Of the 7213 patients 
who were included in the analyses, 4010 (55.6%) 
had STEMI (and underwent randomization a 
median of 3.1 hours after symptom onset) and 
3203 (44.4%) had a non–ST-segment elevation 
acute coronary syndrome at presentation (and 
underwent randomization a median of 36.5 hours 
after symptom onset). A Killip class of more 
than I at presentation was present in 698 pa-
tients (9.7%).
Before angiography, the platelet-aggregation 
inhibitor clopidogrel, ticagrelor, or prasugrel was 
administered in 3312 patients (45.9%), 1713 pa-
tients (23.7%), and 921 patients (12.8%), respec-
tively. Procedural characteristics are shown in 
Table S1 in the Supplementary Appendix. PCI 
was performed in 94.4% of the patients, whereas 
0.6% underwent CABG and 5.0% received medi-
cal management. In the catheterization labora-
tory, 165 patients (4.6%) in the bivalirudin group 
and 933 patients (25.9%) in the heparin group 
received glycoprotein IIb/IIIa inhibitors. Medica-
tions that were prescribed at the time of hospital 
discharge are detailed in Table S2 in the Supple-
mentary Appendix.
Clinical Outcomes
At 30 days, complete follow-up information was 
available for 7188 of 7213 patients (99.7%). Ma-
jor adverse cardiovascular events occurred in 371 
of 3610 patients (10.3%) in the bivalirudin group 
and in 391 of 3603 patients (10.9%) in the hepa-
rin group (rate ratio, 0.94; 95% confidence inter-
val [CI], 0.81 to 1.09; P = 0.44) (Table 3 and 
Fig. 1A). A total of 401 patients (11.2%) in the 
bivalirudin group, as compared with 444 pa-
tients (12.4%) in the heparin group, had a net 
adverse clinical event (rate ratio, 0.89; 95% CI, 
0.78 to 1.03; P = 0.12) (Table 3 and Fig. 1B).
Bivalirudin was associated with a lower rate 
of death from any cause than was heparin (1.7% 
vs. 2.3%; rate ratio, 0.71; 95% CI, 0.51 to 0.99; 
P = 0.04) (Table 3, and Fig. S2A in the Supplemen-
tary Appendix), as well as a lower rate of death 
from cardiac causes (1.5% vs. 2.2%; rate ratio, 
0.68; 95% CI, 0.48 to 0.97; P = 0.03) (Table 3). 
There were no significant differences between 
the bivalirudin group and the heparin group in 
the rates of myocardial infarction, which con-
tributed at least two thirds of the events to the 
two coprimary end points (8.6% and 8.5%, re-
spectively; rate ratio, 1.01; 95% CI, 0.85 to 1.19; 
P = 0.93) (Table 3, and Fig. S2B in the Supple-
mentary Appendix), and stroke (0.4% and 0.5%, 
respectively; rate ratio, 0.81; 95% CI, 0.39 to 
1.68; P = 0.57) (Table 3, and Fig. S2C in the 
Supplementary Appendix). The rate of definite 
stent thrombosis was higher in the bivalirudin 
group than in the heparin group (1.0% vs. 0.6%; 
rate ratio, 1.71; 95% CI, 1.00 to 2.93; P = 0.048), 
whereas the rate of definite or probable events 
did not differ significantly (Table 3).
The rate of major bleeding (BARC 3 or 5) was 
lower in the bivalirudin group than in the hepa-
rin group (1.4% vs. 2.5%; rate ratio, 0.55; 95% CI, 
0.39 to 0.78; P<0.001) (Table 3, and Fig. S2D in 
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the Supplementary Appendix), a difference that 
was driven by non–access-related events (Table 
S3 in the Supplementary Appendix). The rates of 
fatal bleeding and bleeding events fulfilling the 
TIMI major or minor criteria or GUSTO severe 
or moderate criteria were also lower in the bi-
valirudin group (Table S3 in the Supplementary 
Appendix).
Bivalirudin Treatment Duration
The primary composite outcome was reported in 
195 patients (11.0%) who received post-PCI bi-
valirudin and in 215 patients (11.9%) who did 
not receive post-PCI bivalirudin (rate ratio, 0.91; 
95% CI, 0.74 to 1.11; P = 0.34) (Table 3, and 
Fig. 2). There was no significant difference be-
tween the two groups in the risk of definite 
Characteristic Antithrombin-Type Study Treatment-Duration Study
Bivalirudin 
(N = 3610)
Unfractionated 
Heparin 
(N = 3603)
Post-PCI  
Bivalirudin Infusion 
(N = 1799)
No Post-PCI 
 Bivalirudin Infusion 
(N = 1811)
Age
Mean — yr 65.4±11.9 65.4±11.9   65.4±12.1 65.5±11.7
≥75 yr — no. (%) 906 (25.1) 904 (25.1) 463 (25.7) 443 (24.5)
Male sex — no. (%) 2731 (75.7) 2764 (76.7) 1351 (75.1) 1380 (76.2)
Mean weight — kg 77.7±13.7 77.4±13.8   78.2±13.9 77.3±13.6
Body-mass index†
Mean 27.2±4.2 27.0±4.1   27.3±4.3‡ 27.0±4.0‡
≥25 — no. (%) 2435 (67.5) 2405 (66.7) 1226 (68.1) 1209 (66.8)
Diabetes mellitus — no. (%) 815 (22.6) 786 (21.8) 399 (22.2) 416 (23.0)
Insulin-dependent 195 (5.4) 187 (5.2) 112 (6.2)‡ 83 (4.6)‡
Non–insulin-dependent 620 (17.2) 599 (16.6) 287 (16.0) 333 (18.4)
Smoking status — no. (%) 2020 (56.0) 2016 (56.0) 1013 (56.3) 1007 (55.6)
Current smoker 1307 (36.2) 1302 (36.1) 638 (35.5) 669 (36.9)
Previous smoker 713 (19.8) 714 (19.8) 375 (20.8) 338 (18.7)
Hypercholesterolemia — no. (%) 1596 (44.2) 1558 (43.2) 750 (41.7)‡ 846 (46.7)‡
Hypertension — no. (%) 2264 (62.7) 2222 (61.7) 1131 (62.9) 1133 (62.6)
Family history of coronary artery disease — 
 no. (%)
991 (27.5) 992 (27.5) 488 (27.1) 503 (27.8)
Previous myocardial infarction — no. (%) 530 (14.7) 500 (13.9) 279 (15.5) 251 (13.9)
Previous PCI — no. (%) 536 (14.8) 504 (14.0) 275 (15.3) 261 (14.4)
Previous CABG — no. (%) 127 (3.5)‡ 95 (2.6)‡ 64 (3.6) 63 (3.5)
Previous TIA or stroke — no. (%) 181 (5.0) 185 (5.1) 104 (5.8)‡ 77 (4.3)‡
Peripheral vascular disease — no. (%) 296 (8.2) 284 (7.9) 167 (9.3)‡ 129 (7.1)‡
Chronic obstructive pulmonary disease —  
no. (%)
216 (6.0) 220 (6.1) 107 (5.9) 109 (6.0)
Pulmonary hypertension — no. (%) 5 (0.1) 5 (0.1) 4 (0.2) 1 (0.1)
Renal failure — no. (%) 48 (1.3) 47 (1.3) 22 (1.2) 26 (1.4)
Dialysis — no. (%) 5 (0.1) 2 (0.1) 0 5 (0.3)
*  Plus–minus values are means ±SD. There were no significant differences between the groups, except as noted. CABG denotes coronary- 
artery bypass grafting, PCI percutaneous coronary intervention, and TIA transient ischemic attack.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  P<0.05 for the between-group comparison.
Table 1. Characteristics of the Patients at Baseline.*
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Characteristic Antithrombin-Type Study Treatment-Duration Study
Bivalirudin 
(N = 3610)
Unfractionated 
Heparin 
(N = 3603)
Post-PCI  
Bivalirudin Infusion 
(N = 1799)
No Post-PCI 
 Bivalirudin Infusion 
(N = 1811)
Clinical presentation
Cardiac arrest — no. (%) 79 (2.2) 82 (2.3) 36 (2.0) 43 (2.4)
Killip class — no. (%)
I 3275 (90.7) 3240 (89.9) 1641 (91.2) 1634 (90.2)
II 224 (6.2) 264 (7.3) 115 (6.4) 109 (6.0)
III 76 (2.1) 64 (1.8) 29 (1.6) 47 (2.6)
IV 35 (1.0) 35 (1.0) 14 (0.8) 21 (1.2)
ST-segment elevation myocardial infarction —  
no. (%)
2012 (55.7) 1998 (55.5) 1006 (55.9) 1006 (55.5)
Previous lytic therapy — no. (%) 97 (2.7) 101 (2.8) 47 (2.6) 50 (2.8)
Non–ST-segment elevation acute coronary syn-
drome — no. (%)
1598 (44.3) 1605 (44.5) 793 (44.1) 805 (44.5)
Troponin-negative 165 (4.6) 163 (4.5) 72 (4.0) 93 (5.1)
Troponin-positive 1433 (39.7) 1442 (40.0) 721 (40.1) 712 (39.3)
ST-segment deviation 747 (20.7) 742 (20.6) 357 (19.8) 390 (21.5)
T-wave inversion 450 (12.5)† 506 (14.0)† 234 (13.0) 216 (11.9)
Systolic arterial pressure — mm Hg 138.6±25.9 138.2±25.9 138.5±25.8 138.7±26.1
Heart rate — beats/min 76.2±16.9 75.8±16.4 76.0±17.3 76.5±16.5
Left ventricular ejection fraction — % 50.5±9.5 50.9±9.5 50.3±9.5 50.7±9.6
Estimated glomerular filtration rate — ml/
min/1.73 m2
83.3±25.1 84.2±25.7 83.5±25.4 83.3±24.8
Medications administered before catheterization 
procedure — no. (%)
Aspirin 3413 (94.5) 3376 (93.7) 1707 (94.9) 1706 (94.2)
Clopidogrel 1698 (47.0) 1614 (44.8) 834 (46.4) 864 (47.7)
Prasugrel 456 (12.6) 465 (12.9) 227 (12.6) 229 (12.6)
Ticagrelor 858 (23.8) 855 (23.7) 434 (24.1) 424 (23.4)
Enoxaparin 540 (15.0) 553 (15.3) 257 (14.3) 283 (15.6)
Fondaparinux 339 (9.4) 337 (9.4) 172 (9.6) 167 (9.2)
Angiotensin-converting–enzyme inhibitor 994 (27.5) 1020 (28.3) 493 (27.4) 501 (27.7)
Angiotensin-receptor antagonist 361 (10.0) 346 (9.6) 183 (10.2) 178 (9.8)
Statin 1463 (40.5) 1448 (40.2) 707 (39.3) 756 (41.7)
Beta-blocker 1408 (39.0) 1356 (37.6) 686 (38.1) 722 (39.9)
Warfarin 56 (1.6) 44 (1.2) 34 (1.9) 22 (1.2)
Proton-pump inhibitor 1763 (48.8) 1780 (49.4) 900 (50.0) 863 (47.7)
Unfractionated heparin 1166 (32.3) 1183 (32.8) 591 (32.9) 575 (31.8)
Bivalirudin 2 (0.1) 3 (0.1) 0 2 (0.1)
Glycoprotein IIb/IIIa inhibitor 5 (0.1) 7 (0.2) 2 (0.1) 3 (0.2)
*  Plus–minus values are means ±SD. There were no significant differences between the groups, except as noted.
†  P<0.05 for the between-group comparison.
Table 2. Clinical Presentation and Medications at Baseline.*
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stent thrombosis, although the rate of subacute 
definite stent thrombosis was significantly high-
er in the group that received a post-PCI bivaliru-
din infusion (Table 3). In addition, there was no 
significant between-group difference in the rate 
of bleeding according to the BARC and TIMI 
scales, except for the rate of BARC 2 bleeding, 
which was higher in the group that received 
post-PCI bivalirudin, and in rates of BARC 3 or 
5 and GUSTO bleeding, which were lower in the 
post-PCI bivalirudin group (Table 3, and Tables 
S3 and S4 in the Supplementary Appendix).
Additional Analyses
The effect of bivalirudin versus heparin on the 
rates of the two coprimary outcomes, death 
from any cause, and major bleeding was consis-
tent across subgroups, including in analyses that 
were stratified according to PCI access site (Fig. 
S3 in the Supplementary Appendix). The effect of 
the duration of bivalirudin treatment on ischemic 
and bleeding outcomes was also consistent across 
subgroups (Fig. S4 in the Supplementary Appen-
dix). Ischemic and bleeding outcomes stratified 
according to the planned use of glycoprotein IIb/
IIIa inhibitors in the heparin group or the post-
PCI bivalirudin regimen are provided in Table S5 
in the Supplementary Appendix. The effect of 
the dose of heparin on bleeding is shown in 
Table S6 in the Supplementary Appendix.
Discussion
Among patients with an acute coronary syn-
drome with or without ST-segment elevation, the 
rates of major adverse cardiovascular events and 
net adverse clinical events were not significantly 
lower among those who received bivalirudin 
than among those who received unfractionated 
heparin at the time of PCI. Similarly, post-PCI 
infusion of bivalirudin, as compared with no 
post-PCI infusion, did not affect the primary 
study outcome. Hence, none of three null hy-
potheses of the program could be rejected.
In a secondary analysis, the rate of death 
from any cause was 0.6 percentage points lower 
with bivalirudin than with heparin (relative risk 
reduction, 29%), owing to an absolute difference 
of 0.7 percentage points in the rate of cardiac 
death. This treatment difference was associated 
with lower rates of bleeding, including non–
access-related and fatal bleeding. There was no 
significant difference between the groups in the 
rate of definite or probable stent thrombosis, 
although the rate of definite stent thrombosis 
was higher in the bivalirudin group.
Post-PCI infusion of bivalirudin did not result 
in lower rates of definite stent thrombosis at 
30 days than the rates with no post-PCI infusion. 
Overall, there were no significant between-group 
differences in the rates of BARC or TIMI bleed-
ing, whereas the rates of BARC 3 or 5 or GUSTO 
bleeding were lower in the group that received 
post-PCI bivalirudin than in the group that did 
not receive a post-PCI infusion. An excess of 
nine episodes of pericardial bleeding in the 
group that received no post-PCI bivalirudin infu-
sion largely explained the difference in bleeding 
rates between the two study groups.
Our results reinforce the concept that reduc-
ing the rate of major bleeding events among 
patients with acute coronary syndromes who are 
treated with PCI does not necessarily affect the 
risk of major ischemic adverse cardiovascular 
events.6,7,10 However, the rates of composite out-
comes that included both ischemic events and 
bleeding (i.e., net adverse cardiovascular events 
in our trial) were not significantly lower with 
bivalirudin than with heparin; these findings 
contrast with the results of the Acute Catheter-
ization and Urgent Intervention Triage Strategy 
(ACUITY)6 and Harmonizing Outcomes with 
Revascularization and Stents in Acute Myocar-
dial Infarction (HORIZONS-AMI)7 studies. The 
difference between the findings of our study and 
those of the other studies may reflect the way in 
which nonfatal periprocedural ischemic events 
(which appear to be unaffected by the type of 
antithrombin agent) and bleeding events (which 
appear to be lower with bivalirudin than with 
heparin) were defined, since the definition of 
these events ultimately drives the relative contri-
bution of each within the composite outcome. In 
our study, the use of transfusion in patients 
without overt bleeding did not satisfy the criteria 
for major bleeding, in contrast to criteria used in 
previous studies of bivalirudin.6-8 In addition, 
reinfarction (mostly periprocedural) contributed 
to up to 80% of events in the two coprimary end 
points and occurred at a higher rate than was 
anticipated on the basis of previous trials.11 This 
finding may have been a result of the definition 
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of reinfarction that we used in our study, a cri-
terion that was in agreement with the third 
universal definition of myocardial infarction 
and used troponin as the preferred biomarker of 
myocardial necrosis,18,19 even though it also re-
quired the presence of new symptoms or signs 
of myocardial ischemia.
The lower rate of bleeding in the bivalirudin 
group than in the heparin group among pa-
tients with acute coronary syndromes who were 
undergoing PCI was associated with lower mor-
tality, a finding that was consistent with those 
in the HORIZONS-AMI trial7 and a pooled 
analysis of results from the HORIZONS-AMI 
trial and the European Ambulance Acute Coro-
nary Syndrome Angiography (EUROMAX) trial.20,21 
Fatal bleeding events, which were mostly non–
access-related, were lower by 0.3 percentage 
points in the bivalirudin group than in the hepa-
rin group (relative risk reduction, 69%), which 
explains half the 0.6-percentage-point lower 
rate of death from any cause in the bivalirudin 
group.
In our study, the use of radial or femoral ac-
cess, which was randomly assigned, did not 
prove to be an effect modifier in the bivalirudin 
group for any of the major outcomes. Unfrac-
tionated heparin was administered according to 
guidelines, at a mean dose of 78 units per kilo-
gram in the control group.13,14 Hence, the results 
of our study do not support the concern that the 
bleeding benefit in the bivalirudin group is at-
tributable to routine use of femoral access or a 
high heparin dose in control patients.21
Our study confirmed an excess of definite 
stent thrombosis among patients in the bivali-
rudin group; this higher rate in the bivalirudin 
group than in the heparin group appeared to 
be less pronounced on either an absolute basis 
(0.4 percentage points) or a relative basis (71%) 
than that reported previously.7-9 This finding 
may reflect the inclusion of patients with non–
ST-segment elevation acute coronary syndromes,10 
the early administration of oral P2Y12 inhibitors,
22 
or both. Prolonging the administration of bivali-
rudin well after completion of the intervention 
did not result in a lower risk of definite stent 
thrombosis after coronary revascularization, a 
finding that was consistent with the results of 
the EUROMAX study. It remains unclear whether 
the post-PCI bivalirudin regimen, which was left 
to the discretion of the treating physicians in O
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our study and in previous studies, influenced 
ischemic or bleeding risks.
One limitation of our trial is that the protocol 
allowed for two different regimens of post-PCI 
bivalirudin infusion in the bivalirudin group and 
for discretionary use of glycoprotein IIb/IIIa in-
hibitors in the heparin group. These features of 
the trial design are consistent with current prac-
tice, but they make the study results more dif-
ficult to interpret. In addition, we did not correct 
Figure 1. Coprimary Composite Study Outcomes at 30 Days.
Panel A shows the cumulative incidence of the coprimary outcome of major adverse cardiovascular events, which 
were defined as a composite of death from any cause, myocardial infarction, or stroke, up to 30 days, among pa-
tients receiving either bivalirudin or unfractionated heparin. Panel B shows the rate of net adverse clinical events, 
which were defined as a composite of major bleeding that was not related to coronary-artery bypass grafting (Bleed-
ing Academic Research Consortium [BARC] type 3 or 5) or major adverse cardiovascular events up to 30 days. The 
insets show the same data on an enlarged y axis.
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for multiple testing of secondary end points, 
such as death and stent thrombosis. Therefore, 
for these end points, differences with borderline 
P values should be interpreted with caution, 
since they may have occurred by chance alone.
In conclusion, among patients with acute 
coronary syndromes undergoing invasive treat-
ment, neither the rate of major adverse cardio-
vascular events nor the rate of net adverse clini-
cal events was significantly lower with bivalirudin 
than with unfractionated heparin and discre-
tionary use of glycoprotein IIb/IIIa inhibitors. 
The post-PCI infusion of bivalirudin for at least 
4 hours after the intervention did not result in a 
lower rate of the composite outcome of ischemic 
and bleeding events, including stent thrombosis, 
than the rate with no post-PCI infusion.
Supported by the Medicines Company and Terumo Medical.
Dr. Valgimigli reports receiving fees for serving on advisory 
boards from AstraZeneca and St. Jude Vascular, lecture fees 
from AstraZeneca, the Medicines Company, Terumo Medical, 
St. Jude Vascular, Alvimedica, Abbott Vascular, and Correvio, 
travel support from the Medicines Company, and grant support 
through his institution from AstraZeneca; Dr. Leonardi, re-
ceiving fees for serving on advisory boards from the Medicines 
Company; Dr. Andò, receiving fees for serving on an advisory 
board from Daiichi Sankyo, lecture fees from St. Jude Medical 
and Bayer Healthcare, and travel support from Menarini, Ab-
bott Vascular, Biotronik, and Eli Lilly/Daiichi Sankyo; Dr. 
Limbruno, receiving fees for lectures and serving on advisory 
boards from the Medicines Company, AstraZeneca, Eli Lilly, 
Boston Scientific, Biotronik, and Merck; Dr. Garbo, receiving 
consulting fees from Terumo Medical, Volcano Europe, and 
CID-Alvimedica and lecture fees from CID-Alvimedica and Ab-
bott Vascular; Dr. Cortese, receiving fees for serving on an ad-
visory board from Abbott Vascular, lecture fees from Abbott 
Vascular, the Medicines Company, Hexacath, AB Medica, and 
AstraZeneca, and grant support from Medtronic, Movi, and AB 
Medica; Dr. Santarelli, receiving fees for serving on a clinical-
events committee from CID; Dr. Varbella, receiving fees for 
serving on advisory boards from AstraZeneca, Eli Lilly/Daiichi 
Sankyo, and Abbott Vascular, lecture fees from AstraZeneca 
and Eli Lilly/Daiichi Sankyo, travel support from Biosensors 
International, and grant support from Terumo Medical, Boeh-
ringer Ingelheim, and St. Jude Medical; Dr. van ’t Hof, receiv-
ing lecture fees from Abbott, AstraZeneca, Correvio, and Eli 
Lilly/Daiichi Sankyo, and grant support from Abbott, Astra-
Zeneca, and Eli Lilly/Daiichi Sankyo; Dr. Omerovic, receiving 
fees for serving on advisory boards from AstraZeneca and No-
vartis, lecture fees from Medtronic, and grant support through 
his institution from Abbott; Dr. Sabaté, receiving fees for lec-
tures and serving on advisory boards from Abbott Vascular; 
and Dr. Jüni, serving as an unpaid member of steering com-
mittees on trials funded by AstraZeneca, Biotronik, Biosensors 
Figure 2. Primary Composite Outcome at 30 Days, According to Duration of Bivalirudin Infusion.
Shown is the cumulative incidence of the primary outcome for the treatment-duration subgroup of patients who 
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compared with those who were assigned not to receive a post-PCI infusion, which was a composite of urgent target-
vessel revascularization, definite stent thrombosis, or net adverse clinical events up to 30 days. The inset shows the 
same data on an enlarged y axis.
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